Test of CAR T-cell therapy for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and willing to sign informed consent
- Have confirmed aggressive large B-cell lymphoma that has come back or is resistant to treatment
- Have had enough prior cancer treatments (at least two, depending on the study group)
- Have at least one measurable lymphoma spot seen on scans
- Have blood counts high enough for treatment: neutrophils, platelets, and lymphocytes
- Be able to be eligible based on heart/cancer-timing rules the study explains (other protocol checks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
Hear when a new Relapsed Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.